See more : SomaLogic, Inc. (SLGCW) Income Statement Analysis – Financial Results
Complete financial analysis of Scancell Holdings plc (SCNLF) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Scancell Holdings plc, a leading company in the Biotechnology industry within the Healthcare sector.
You may be interested
- ALi Corporation (3041.TW) Income Statement Analysis – Financial Results
- Fuan Pharmaceutical (Group) Co., Ltd. (300194.SZ) Income Statement Analysis – Financial Results
- Matsa Resources Limited (MAT.AX) Income Statement Analysis – Financial Results
- International Medical Center of Biomaterials Processing and Cryostorage Public Joint-stock company (GEMA.ME) Income Statement Analysis – Financial Results
- JAWS Hurricane Acquisition Corporation (HCNEU) Income Statement Analysis – Financial Results
Scancell Holdings plc (SCNLF)
About Scancell Holdings plc
Scancell Holdings plc, a clinical stage biopharmaceutical company, engages in the discovery and development of novel vaccines and antibody medicines to treat unmet needs in cancer and infectious diseases. The company's product candidates include SCIB1, an ImmunoBody cancer vaccine for the treatment of metastatic melanoma; SCIB2/iSCIB2 vaccine, which is under evaluation for the treatment of patients with solid tumours, including non-small cell lung cancer; and Modi-1 that is in phase I/II clinical trials for the treatment of head and neck, triple negative breast, ovarian, and renal cancers. It also develops Modi-2, which targets homocitrullinated cancer antigens. In addition, the company develops SCOV1 and SCOV2 COVIDITY, a DNA vaccine against the SARS-CoV-2 virus. Scancell Holdings plc was founded in 1997 and is based in Oxford, the United Kingdom.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 5.27M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Cost of Revenue | 525.00K | 740.00K | 249.00K | 43.00K | 21.06K | 27.61K | 32.58K | 21.89K | 0.00 | 0.00 | 0.00 | 0.00 | 849.00K | 1.09M | 676.00K |
| Gross Profit | 4.75M | -740.00K | -249.00K | -43.00K | -21.06K | -27.61K | -32.58K | -21.89K | 0.00 | 0.00 | 0.00 | 0.00 | -849.00K | -1.09M | -676.00K |
| Gross Profit Ratio | 90.04% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Research & Development | 11.65M | 9.48M | 6.41M | 4.67M | 4.15M | 2.86M | 2.77M | 2.01M | 2.00M | 1.68M | 1.45M | 1.22M | 849.00K | 1.09M | 676.00K |
| General & Administrative | 5.02M | 4.79M | 3.35M | 2.12M | 2.58M | 2.09M | 1.78M | 1.03M | 961.63K | 820.11K | 731.67K | 740.13K | 12.00K | 0.00 | 0.00 |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 5.02M | 4.79M | 3.35M | 2.12M | 2.58M | 2.09M | 1.78M | 1.03M | 961.63K | 820.11K | 731.67K | 740.13K | 12.00K | 0.00 | 0.00 |
| Other Expenses | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Operating Expenses | 16.67M | 13.30M | 8.83M | 6.78M | 6.73M | 4.94M | 4.55M | 3.04M | 2.96M | 2.50M | 2.18M | 1.96M | 885.00K | 714.00K | 215.00K |
| Cost & Expenses | 17.19M | 13.30M | 8.83M | 6.78M | 6.73M | 4.94M | 4.55M | 3.04M | 2.96M | 2.50M | 2.18M | 1.96M | 1.73M | 1.81M | 891.00K |
| Interest Income | 284.00K | 4.00K | 3.00K | 14.00K | 15.00K | 2.75K | 53.45K | 13.55K | 131.51K | 29.19K | 30.04K | 31.41K | 10.00K | 2.00K | 57.00K |
| Interest Expense | 1.22M | 2.88M | 1.65M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Depreciation & Amortization | 902.00K | 740.00K | 249.00K | 43.00K | 21.06K | 27.61K | 32.58K | 21.89K | 29.12K | 38.96K | 44.01K | 35.98K | 33.00K | 23.00K | 28.00K |
| EBITDA | -12.19M | -7.31M | -9.64M | -6.74M | -6.71M | -4.91M | -4.52M | -3.02M | -2.93M | -2.46M | -2.14M | -1.93M | -1.70M | -1.78M | -863.00K |
| EBITDA Ratio | -231.21% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Operating Income | -11.92M | -13.30M | -8.83M | -6.78M | -6.73M | -4.94M | -4.55M | -3.04M | -2.96M | -2.50M | -2.18M | -1.96M | -1.73M | -1.81M | -891.00K |
| Operating Income Ratio | -226.14% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Total Other Income/Expenses | -2.38M | 9.53M | -7.05M | 14.00K | 14.99K | 2.75K | 53.45K | 13.55K | 131.51K | 29.19K | 30.04K | 31.41K | 9.75K | 2.00K | 57.00K |
| Income Before Tax | -14.30M | -3.77M | -16.81M | -6.77M | -6.71M | -4.94M | -4.50M | -3.03M | -2.83M | -2.47M | -2.15M | -1.93M | -1.72M | -1.80M | -834.00K |
| Income Before Tax Ratio | -271.37% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Income Tax Expense | -2.37M | -1.70M | -1.33M | -1.26M | -1.09M | -744.54K | -950.41K | -446.34K | -413.85K | -245.08K | -252.01K | -2.52M | -75.00K | -66.00K | -48.00K |
| Net Income | -11.94M | -2.07M | -15.48M | -5.51M | -5.63M | -4.19M | -3.54M | -2.58M | -2.41M | -2.22M | -1.90M | 557.06K | -1.65M | -1.74M | -786.00K |
| Net Income Ratio | -226.45% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| EPS | -0.02 | 0.00 | -0.02 | -0.01 | -0.01 | -0.01 | -0.01 | -0.01 | -0.01 | -0.01 | -0.01 | 0.00 | -0.01 | -0.02 | 0.00 |
| EPS Diluted | -0.01 | 0.00 | -0.02 | -0.01 | -0.01 | -0.01 | -0.01 | -0.01 | -0.01 | -0.01 | -0.01 | 0.00 | -0.01 | -0.02 | 0.00 |
| Weighted Avg Shares Out | 795.73M | 815.54M | 678.89M | 466.19M | 395.42M | 319.44M | 267.27M | 233.13M | 230.54M | 222.72M | 199.87M | 191.36M | 163.75M | 110.31M | 163.69M |
| Weighted Avg Shares Out (Dil) | 816.05M | 815.54M | 678.89M | 466.19M | 395.42M | 319.44M | 267.96M | 233.13M | 231.20M | 222.72M | 218.76M | 210.24M | 163.75M | 110.31M | 163.69M |
Scancell outlines plans to raise up to £9.5m to support clinical plans
Scancell Holdings PLC (AIM:SCLP, OTC:SCNLF) has announced plans to raise up to £9.5 million to support its clinical programmes. The funding round is made up of a placing of new shares at 10.5p each that will bring in at least £8.5...
Scancell's latest deal is only part of the story for this ambitious cancer vaccine specialist
For ambitious junior life sciences companies, often the ultimate goal is securing partnerships with well-funded industry players to propel drug development toward commercial success. For many smaller innovators, bringing a promising molecule from the lab through clinical trials and onto...
Scancell Holdings shares jump 9% following high-value licensing announcement
Scancell Holdings PLC (AIM:SCLP, OTC:SCNLF) shares are up 9% this Wednesday after the clinical-stage biotech company announced a licensing agreement with Genmab (CSE:GEN) worth up to $630 million in payments. The agreement grants Genmab exclusive global rights to develop and...
Scancell strikes deal worth up to $630m with Genmab
Scancell Holdings PLC (AIM:SCLP, OTC:SCNLF) has unveiled a licensing agreement with Genmab (CSE:GEN) that could generate up to $630 million in payments, alongside royalties. The deal gives the Danish biotech exclusive global rights to develop and commercialise a monoclonal antibody from...
Scancell's new CEO takes the helm of a cancer immunotherapy specialist in rude health
Dr Phil L'Hullier begins his tenure as CEO of Scancell Holdings PLC (AIM:SCLP, OTC:SCNLF) at a pivotal moment, coinciding with significant clinical progress for its lead asset, SCIB1. This DNA-based cancer vaccine has shown promise in treating advanced melanoma, but Scancell's...
Scancell trial update 'very positive', says broker
Panmure Liberum repeated its 'buy' recommendation for Scancell Holdings PLC (AIM:SCLP, OTC:SCNLF) shares after what it described as a 'very positive' update from its phase II SCOPE clinical trial. The study is designed to assess the potential of the cancer vaccine, SCIB1.
Scancell's chief scientist hails 'excellent' melanoma data
Scancell Holdings PLC's (AIM:SCLP, OTC:SCNLF) chief scientist, Professor Lindy Durrant, hailed results from the ongoing SCOPE trial for advanced melanoma as “excellent”. The study tested Scancell's SCIB1 immunotherapy in combination with two checkpoint inhibitor drugs, ipilimumab and nivolumab, in 25 patients.
Scancell appointment wins City favour as shares rise 11%
The appointment of Dr. Phil L'Huillier as CEO brings essential company development expertise to Scancell Holdings PLC (AIM:SCLP, OTC:SCNLF), enhancing its strong scientific foundation and helping the company progress to its next stage of growth.
Scancell names Dr Phil L'Huillier new CEO
Scancell Holdings PLC (AIM:SCLP, OTC:SCNLF), a company developing immunotherapies to treat cancer, has appointed Dr Phil L'Huillier as its new chief executive. He will officially join the company on November 18.
Scancell Holdings sets ambitious roadmap for the next 18 months
Scancell Holdings PLC (AIM:SCLP, OTC:SCNLF) has rolled out its roadmap for the next 18 months, which builds on the significant clinical progress made to date. An early milestone comes from the release of full cohort data for SCIB1 and iSCIB1+ (for...
Source: https://incomestatements.info
Category: Stock Reports